Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1Phase 1 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5

Conditions

Keratosis, Actinic 5Carcinoma, Squamous Cell 1

Interventions

3-ingenyl angelate 37Aminolevulinic Acid 33Imiquimod 25Photochemotherapy 22Fluorouracil 22methyl 5-aminolevulinate 12Gels 12Cryotherapy 12Diclofenac 11tirbanibulin 6Solutions 6BF-200 ALA 6calcipotriene 5Petrolatum 5Ointments 5LEO 43204 5Radiotherapy 4Prilocaine 4Lidocaine 4Therapeutics 3Niacinamide 3Cryosurgery 31-phenyl-3,3-dimethyltriazene 3SR-T100 2Phototherapy 2Imipramine 2Deoxyribonuclease (Pyrimidine Dimer) 2Celecoxib 2Blue Light 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Keratosis, Actinic × LEO 43204 × Clear all
NCT03115476 2025-03-11

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

LEO Pharma

Phase 3 Terminated
563 enrolled 15 charts
Dermatologic

Carcinoma, Squamous Cell, Keratosis, Actinic

NCT02305888 2025-03-10

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

LEO Pharma

Phase 2 Completed
189 enrolled 9 charts
Dermatologic

Keratosis, Actinic

NCT02100813 2025-03-06

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

LEO Pharma

Phase 1/2 Completed
220 enrolled 19 charts
Dermatologic

Keratosis, Actinic

NCT02120456 2025-03-06

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

LEO Pharma

Phase 1/2 Completed
224 enrolled 21 charts
Dermatologic

Keratosis, Actinic

NCT02650505 2025-02-24

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

LEO Pharma

Phase 1 Completed
233 enrolled
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡